Showing results (201-210 of 227) with videos related to

Sort By:
Pageof 23
Neuro-Oncology|October 22, 2022
Palliative care and end-of-life care in adults with malignant brain tumorsJohan A F Koekkoek, Pim B van der Meer, Andrea Pace, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)Giuseppe Lombardi, Paola Del Bianco, Alba A Brandes, et al.
Cell Death & Disease|December 13, 2023
Chlorpromazine affects glioblastoma bioenergetics by interfering with pyruvate kinase M2Claudia Abbruzzese, Silvia Matteoni, Paola Matarrese, et al.
Future Oncology (London, England)|May 28, 2021
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trialAlessandra Fabi, Irene Terrenato, Antonello Vidiri, et al.
Journal of Inorganic Biochemistry|February 19, 2017
The dissociation of the Hsp60/pro-Caspase-3 complex by bis(pyridyl)oxadiazole copper complex (CubipyOXA) leads to cell death in NCI-H292 cancer cellsCeleste Caruso Bavisotto, Dragana Nikolic, Antonella Marino Gammazza, et al.
Bioorganic & Medicinal Chemistry|December 4, 2014
New potent antibacterials against Gram-positive multiresistant pathogens: effects of side chain modification and chirality in linezolid-like 1,2,4-oxadiazolesCosimo G Fortuna, Roberto Berardozzi, Carmela Bonaccorso, et al.
Current Pharmaceutical Design|October 25, 2012
Hsp60, a novel target for antitumor therapy: structure-function features and prospective drugs designAndrea Pace, Giampaolo Barone, Antonino Lauria, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 25, 2026
Mapping integrated care for brain tumour-related epilepsy in the Italian RIN-IRCCS networkElena Anghileri, Alessia Marcassoli, Veronica Villani, et al.
Future Oncology (London, England)|April 13, 2019
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?Veronica Villani, Alessandra Fabi, Antonio Tanzilli, et al.
Pageof 23